Aktis Oncology, Inc.

Aktis Oncology, Inc. is a clinical-stage oncology company that develops targeted radiopharmaceuticals for a broad range of cancer patients. The company aims to expand the use of targeted radiopharmaceuticals beyond existing technologies and targets. While current marketed radiopharmaceutical products, which target prostate specific membrane antigen or somatostatin-2 receptor, are approved for only one tumor type each, Aktis Oncology sees an opportunity to develop next-generation technologies. These technologies are designed to expand the types of tumor targets that can be safely treated with alpha-emitting radioisotopes. To support its development efforts, Aktis Oncology is building an efficient end-to-end supply chain, combining internal capabilities with external vendors. The company's goal is to maximize the clinical utility of its products across multiple indications and tumor types, and to increase the commercial adoption of radiopharmaceuticals in the broader clinical oncology setting, beyond traditional nuclear medicine. Aktis Oncology has developed a proprietary miniprotein radioconjugate platform. This platform is designed to deliver the tumor-killing properties of radioisotopes selectively to targeted tumors. The miniprotein radioconjugates are engineered for high tumor penetration and prolonged tumor retention, while rapidly clearing from normal organs and tissues to minimize systemic radiation exposure. The company's miniproteins have shown the ability to bind effectively to tumor targets that are not addressed by current delivery technologies, such as peptide-based radioconjugates.